Penny stock below Rs 2: Company secures USD 21 million export deal, Expands globally via Singapore subsidiary and Completes strong rights issue!

Remedium Lifecare Limited is strategically repositioning itself for long-term growth in the pharmaceutical sector, aiming to transform into a fully integrated solutions provider. A key element of this strategy is the establishment of REMLIFE GLOBAL PTE. LTD. in Singapore, a wholly-owned subsidiary that now serves as Remedium's global interface for commercial and capital markets. This move is designed to enhance international operations, broaden market reach and attract global investors.

In line with its global expansion, Remedium secured a significant multi-year export contract worth ¥182.7 crore (USD 21 million) in February 2025 with a leading pharmaceutical distributor. This contract underscores the company's successful transition from a trading-led model to a comprehensive CDMO (Contract Development and Manufacturing Organization) platform, emphasising quality, regulatory compliance and customised innovation for its clients worldwide.

Strong investor confidence in Remedium's future potential was evident through robust participation in its recent Rights Issue. The capital raised is being strategically deployed to critical areas, including R&D upgrades, enhancing CDMO infrastructure and expanding into regulated and semi-regulated international markets. The company is also investing in advanced quality control and testing facilities to bolster its analytical and formulation capabilities for its growing CDMO client base.

Remedium is further solidifying its innovation pipeline by partnering with Jia Yu Lifesciences PTE Ltd via its Singapore subsidiary. This collaboration focuses on green chemistry, aiming to replace animal-origin raw materials with sustainable bioprocesses. With a maturing global order book, diversified sourcing across multiple regions and embedded inventory buffers, Remedium is well-prepared to navigate market complexities and deliver high-value pharmaceutical products.

About the Company

Founded in 1988, Remedium Lifecare Ltd. is a BSE-listed pharmaceutical company engaged in the trading and distribution of raw materials as a supply chain management for the pharmaceutical industry with an emphasis on quality, compliance and global reach. The company continues to expand its presence while playing a pivotal role in India’s pharmaceutical ecosystem.

Remedium Lifecare Ltd has a market cap of over Rs 100 crore. According to the shareholding pattern, the company's promoters own only a 1.13 per cent stake in the company and the maximum stake is owned by the public shareholders, i.e. 98.87 per cent stake. The stock is up by 48 per cent from its 52-week low and has given multibagger returns of over 800 per cent in 5 years.

Disclaimer: The article is for informational purposes only and not investment advice.